Aligos Therapeutics, Inc. (ALGS) Tops Q2 EPS by 7c

Aligos Therapeutics, Inc. (NASDAQ: ALGS) reported Q2 EPS of ($0.43), $0.07 better than the analyst estimate of ($0.50).

For earnings history and earnings-related data on Aligos Therapeutics, Inc. (ALGS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c